Anti-EGFR monoclonal antibodies enhance sensitivity to DNA-damaging agents in BRCA1 -mutated and PTEN -wild-type triple-negative breast cancer cells
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Anti-EGFR monoclonal antibodies enhance sensitivity to DNA-damaging agents in BRCA1
-mutated and PTEN
-wild-type triple-negative breast cancer cells
Authors
Keywords
-
Journal
MOLECULAR CARCINOGENESIS
Volume 56, Issue 5, Pages 1383-1394
Publisher
Wiley
Online
2016-11-19
DOI
10.1002/mc.22596
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Multicentric neoadjuvant pilot Phase II study of cetuximab combined with docetaxel in operable triple negative breast cancer
- (2015) J.M. Nabholtz et al. INTERNATIONAL JOURNAL OF CANCER
- Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact
- (2014) J. M. Nabholtz et al. ANNALS OF ONCOLOGY
- Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study
- (2014) Timothy J Price et al. LANCET ONCOLOGY
- p38α MAPK pathway: A key factor in colorectal cancer therapy and chemoresistance
- (2014) Valentina Grossi WORLD JOURNAL OF GASTROENTEROLOGY
- Randomized Phase II Study of the Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer
- (2013) José Baselga et al. JOURNAL OF CLINICAL ONCOLOGY
- Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents
- (2012) F. Andre et al. ANNALS OF ONCOLOGY
- Effect of KRAS Mutational Status in Advanced Colorectal Cancer on the Outcomes of Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: A Systematic Review and Meta-analysis
- (2012) Albert Y. Lin et al. Clinical Colorectal Cancer
- TBCRC 001: Randomized Phase II Study of Cetuximab in Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer
- (2012) Lisa A. Carey et al. JOURNAL OF CLINICAL ONCOLOGY
- Comprehensive molecular portraits of human breast tumours
- (2012) Daniel C. Koboldt et al. NATURE
- PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition
- (2012) Yasir H. Ibrahim et al. Cancer Discovery
- Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
- (2011) Brian D. Lehmann et al. JOURNAL OF CLINICAL INVESTIGATION
- Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status
- (2011) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Loss of PTEN expression predicts resistance to EGFR-targeted monoclonal antibodies in patients with metastatic colorectal cancer
- (2010) C Mao et al. BRITISH JOURNAL OF CANCER
- Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes
- (2010) Mothaffar F. Rimawi et al. CANCER
- Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer
- (2010) Daniel P. Silver et al. JOURNAL OF CLINICAL ONCOLOGY
- Triple-Negative Breast Cancer
- (2010) William D. Foulkes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer
- (2009) B. Corkery et al. ANNALS OF ONCOLOGY
- Breast cancer cell response to genistein is conditioned by BRCA1 mutations
- (2009) Maud Privat et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines
- (2009) Antoinette Hollestelle et al. BREAST CANCER RESEARCH AND TREATMENT
- p38 Mitogen-Activated Protein Kinase Is Essential for Skin Tumor Development in Mice
- (2009) E. M. Schindler et al. CANCER RESEARCH
- Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy
- (2009) E. Martinelli et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- p53 as a Specific Prognostic Factor in Triple-negative Breast Cancer
- (2009) B. J. Chae et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Analysis of PTEN, BRAF, and EGFR Status in Determining Benefit From Cetuximab Therapy in Wild-Type KRAS Metastatic Colon Cancer
- (2009) Pierre Laurent-Puig et al. JOURNAL OF CLINICAL ONCOLOGY
- Pathologic Complete Response Rates in Young Women With BRCA1-Positive Breast Cancers After Neoadjuvant Chemotherapy
- (2009) Tomasz Byrski et al. JOURNAL OF CLINICAL ONCOLOGY
- Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients
- (2008) T. Byrski et al. BREAST CANCER RESEARCH AND TREATMENT
- How basal are triple-negative breast cancers?
- (2008) François Bertucci et al. INTERNATIONAL JOURNAL OF CANCER
- Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer
- (2008) Cornelia Liedtke et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation